Cambridge Heart, Inc. is a healthcare company engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. The company’s diagnostic products incorporate technology for the measurement of Microvolt T-Wave Alternans (MTWA), a subtle beat-to-beat fluctuation in the T-wave segment of the electrocardiogram (ECG), which is a marker of SCA risk. Microvolt T-Wave Alternans is a non-invasive, clinically-proven, reimbursable test that can help identify patients at risk for sudden cardiac arrest. MTWA technology is available on a number of platforms including the CH2000 and HearTwave II cardiac diagnostic systems. The Company’s products include HearTwave II system, CH2000, MTWA for Q-Stress and Micro-V Alternans Sensors. Cambridge Heart also offers a selection of accessories and supplies including treadmills, patient cables, printers, paper, and additional accessories.
|Headquarters||100 AMES POND ROAD|
TEWKSBURY, MA, United States 1876
|President, Treasurer, Secretary, Director||Craig Jalbert|
|Shares Out.||100.1M||Book Value||$-0.13|
|Cambridge Heart Inc does not pay a dividend.||P/E||--|
|P/Cash Flow (TTM)||--|
*GAAP = prior to non-GAAP analyst adjusted earnings.